BIA Separations Selected For Manufacturing Process Development Support For Gene Therapy Pipeline

BIA Separations, a leading biochromatography development and manufacturing company, today announced it is collaborating with AveXis, a Novartis company, to enhance the commercial purification process for its gene therapy pipeline, beginning with Zolgensma® (onasemnogene abeparvovec-xioi), the first U.S. Food and Drug Administration-approved gene therapy indicated for the treatment of pediatric patients with spinal muscular atrophy (SMA) who are less than two years of age.

Zolgensma is a one-time infusion that provides a functional copy of the human SMN gene to halt disease progression through sustained SMN protein expression.

BIA was selected as a result of its expertise in viral and DNA purification, particularly adeno-associated virus (AAV), and chromatographic technology for the purification and analysis of biomolecules. – Bio Space